Figure 4
From: Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
(a) The distribution of all grades of toxicities considered at least possibly related to the drug administration. (b) The incidence of hematological toxicity across individual cycles, highlighting lack of any cumulative hematological toxicity.
